Duchenne muscular dystrophy (DMD) is an X-linked disorder affecting one in 5,000 live male births which makes it the most common and most severe form of muscular dystrophy. 1 The absence of the protein dystrophin leads to symptom onset typically between the ages of two to five years, with abnormal gait and frequent falls being hallmark signs. 2, 3 Other signs may include delays in motor milestones such as sitting, standing independently, climbing and walking, as well as delays in cognitive development. Untreated, patients with DMD will lose ambulation and become wheelchair dependent at a mean age of 9.5 years. 4 In the second decade of life, complications of respiratory, cardiac, and orthopedic origin are common, with death typically occurring in the second or third decade due to respiratory failure and cardiomyopathy.
aspect where this is evident is with the underutilization of corticosteroids in DMD patients despite years of data demonstrating their benefits.
While data from randomized controlled trials have shown benefit of corticosteroids on muscle strength and function, and data from nonrandomized trials have suggested longitudinal benefit, there is not a consensus on the most appropriate steroid regimen. Currently, treatment recommendations lack comparative data on the efficacy of alternative dosing regimens. Relatively recent publications have uncovered differences between countries in the prescription patterns of steroids regimens. The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) trial is aimed at helping to understand the benefits and risks of the most commonly used glucocorticoid regimens in DMD. 11 In the US, the most common glucocorticoid regimens are either prednisone 0.75 mg/kg/day, which is not approved by the FDA for the treatment of DMD or deflazacort 0.9 mg/kg/day imported from outside of the United States. Deflazacort has been used for the treatment of DMD for over 20 years and published data demonstrates it to be a potentially safer and more effective alternative to prednisone. Deflazacort appears to have a positive impact on multiple aspects of the disease and could be used across the entire DMD population regardless of underlying genetic mutation. Efforts to achieve approval for deflazacort from the FDA are close to being submitted for review. As deflazacort may be approved for DMD and available to patients in the US in early 2017, this article summarizes the published literature on deflazacort to help inform DMDtreating physicians on its impact on the disease.
Muscle Strength/Motor Function/Loss of Ambulation
Numerous publications have demonstrated the benefits of deflazacort on muscle strength and function. In a cohort of 54 boys with DMD, where 30 received active treatment and 24 were untreated, Biggar et al., 2001 12 reported that over a 6-year period patients treated with deflazacort were able to climb a flight of stairs to a later age (10.9 ± 1.9 years versus 9.2 ± 1.1 years, p<0.001) and rise from a floor to a later age (10.7 ± 1.9 years versus 8.8 ± 1.4 years, p < 0.001) than untreated boys. Over the six-year period, all of the patients in the non-treatment group lost ambulation, while only seven (23%) in deflazacort treatment group did so and at a significantly later age (12.3 ± 2.7 years versus 9.8 ± 1.8 years, p<0.05). There was also a dramatic increase in the proportion of patients older than 10 years of age who could still walk in the treatment group compared to the non-treatment group (70% versus 0%, p<0.0001). Using the same cohort Alman et al.,
2004
13 described similar results over a longer timeframe, reporting that over a five-to eight-year period patients in the active deflazacort treatment group were able to climb a flight of stairs longer than untreated patients (10.9 ± 1.9 years versus 9.2 ± 1.0 years). Patients in the active deflazacort treatment group remained ambulatory for longer than untreated patients (12.3 ± 2.7 years versus 9.8 ± 1.8 years). 
Cardiac Function
Cardiomyopathy and cardiac dysfunction are major causes of morbidity and mortality in DMD patients. There is some evidence demonstrating benefits of deflazacort on cardiac disease in DMD patients. Mavrogeni et al., 2009 25 examined the myocardium and sternocleidomastoid muscles in patients with DMD using imaging data from magnetic resonance imaging (MRI) and T2 relaxation time mapping. A total of 17 patients who had been treated with deflazacort for a minimum of seven years were compared with a second 17 who had not received any steroid therapy. While the sample size was very small and the MRI measurements were not taken across time, it was found that the cardiac and respiratory musculature of patients who had received deflazacort treatment was better preserved than that of untreated 
Pulmonary Function
As 
Conclusion
There are many reasons for lack of adherence to the DMD care guidelines, including access to care and the availability of specialized neuromuscular clinics across the US and internationally. Despite evidence on the benefits of glucocorticoids in DMD, MD STARnet reported that 54% of eligible patients are not treated with steroids. 27 Specialized centers of excellence should directly enhance compliance to care guidelines. However, further education on the benefits of glucocorticoids is needed. 
